Negative symptoms, anxiety, and depression as mechanisms of change of a 12-month trial of assertive community treatment as part of integrated care in patients with first- and multi-episode schizophrenia spectrum disorders (ACCESS I trial)
Crossref DOI link: https://doi.org/10.1007/s00406-017-0810-1
Published Online: 2017-05-24
Published Print: 2018-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Schmidt, Stefanie J.
Lange, Matthias
Schöttle, Daniel
Karow, Anne
Schimmelmann, Benno G.
Lambert, Martin
Funding for this research was provided by:
AstraZeneca (NCT00617214)
License valid from 2017-05-24